Evidence map›Paper›PMID 41080958›Full record

ArticleFrontiers in medicine2025

A real-world data study of the effect of co-solvent differences on the clinical safety of melphalan for injection.

Guorong Wang, Wenming Chen, Chenwei Zuo, Huang Li, Jianzhou Yan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Guorong WangDepartment of Hematology, Beijing Medical Research Center for Multiple Myeloma, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China.
Wenming ChenDepartment of Hematology, Beijing Medical Research Center for Multiple Myeloma, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China.
Chenwei ZuoSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Huang LiSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Jianzhou YanResearch Center of National Drug Policy and Ecosystem, China Pharmaceutical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to compare the efficacy and safety of myeloablative conditioning with high-dose propylene glycol-free melphalan (PGF-Mel, EVOMELA Methods: This is a single-center, retrospective study of 107 patients with MM. Patients were divided into two groups based on their high-dose myeloablative conditioning regimen before autologous stem cell transplantation (ASCT): the EVOMELA Results: The median time to myeloablation, the median time to platelet engraftment, and the neutrophil nadir were significantly lower in the EVOMELA Conclusion: EVOMELA

Indexed as

autologous stem cell transplantationco-solventEVOMELA®multiple myelomapropylene glycol melphalan

Identifiers

PMID41080958
PMCPMC12510927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.